135613-49-9

Upstream product

• 142757-91-3 <1S-(1α,2α,3α,4α)>-2-<(3-carboxy-7-oxabicyclo<2.2.1>hept-2-yl)methyl>benzenepropanoic acid methyl ester 
• 6630-33-7 ortho-bromobenzaldehyde 
• 135682-55-2 [(1R,2R,3R,4S)-3-(2-{3-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-propyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-yl]-methanol 
• 133027-60-8 Acetic acid (1R,2R,3R,4S)-3-(2-{3-[dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-propyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl ester 
• 133027-57-3 [1S-(1α,2α,3α,4α)]-α-[2-[3-[[Dimethyl-(1,1,2-trimethylpropyl)silyl]oxy]propyl]phenyl]-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol 
• 142757-90-2 [1S-(1α,2α,3α,4α)]-2-[[3-[(Acetyloxy)methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid 
• 142758-00-7 3-[2-((1S,2R,3R,4R)-3-Hydroxymethyl-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl)-phenyl]-propionic acid 
• 133027-56-2 <3-(2-bromophenyl)propoxy>dimethyl(1,1,2-trimethylpropyl)silane 
• 102540-15-8 methyl (2E)-3-(2-bromophenyl)-2-propenoate 
• 52221-92-8 3-(2-bromo-phenyl)-propan-1-ol 
• 66191-86-4 3-(2-bromophenyl)propanoic acid,methyl ester 
• 135682-53-0 <1S-1α,2α,3α,4α>-2-<<3-(hydroxymethyl)-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid, methyl ester 

Downstream Products

• 135613-50-2 C₂₅H₂₉N₃O₄ 
• 406682-72-2 (1R,2R,3R,4S)-3-[2-(3-formyl-7-oxabicyclo[2.2.1]hept-2-yl-methyl)phenyl]propionic acid methyl ester 
• 135613-36-4 anti-<1S-1α,2α,3α,4α>-2-<<3-<<<(phenylamino)carbonyl>hydrazono>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid 
• 135682-58-5 syn-<1S-1α,2α,3α,4α>-2-<<3-<<<(phenylamino)carbonyl>hydrazono>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid 
• 406682-73-3 (1R,2R,3R,4S)-3-[2-(3-carboxy-7-oxabicyclo[2.2.1]hept-2-yl-methyl)phenyl]propionic acid methyl ester 
• 406682-75-5 3-[2-((1S,2R,3R,4R)-3-Isocyanato-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl)-phenyl]-propionic acid methyl ester 

Relevant academic research and scientific papers

Synthesis of the chiral pair of a novel thromboxane antagonist, 3-[2-(3-benzenesulfonylamino-7-oxabicyclo[2.2.1]hept-2-yl-methyl)phenyl] propionic acid

Preparation of the enantiomeric pair of 3-[2-(3-benzenesulfonylamino-7-oxabicyclo[2.2.1]hept-2-yl-methyl)phenyl] propionic acid, a novel thromboxane antagonist is reported. They are synthesized from either enantiomers of known (1R,2R,3R,4S)-3-[2-(3-carbox

Interphenylene 7-oxabicyclo[2.2.1]heptane thromboxane A2 antagonists. Semicarbazone ω-chains

A series of chiral interphenylene 7-oxabicyclo[2.2.1]heptane semicarbazones 19-26 were prepared and evaluated for their in vitro thromboxane (TxA2) antagonistic activity and in vivo duration of action. The potency of 19-26 was found to be highly dependent on the substitution pattern of the interphenylene ring and decreased in the order ortho > meta >> para. SQ 35,091 (25), [1S-(1α,2α,3α,4α)]-2-[[3-[[[(phenylamino)carbonyl]hydrazono] methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, was identified as a potent and long-acting TxA2 antagonist. In human platelet rich plasma SQ 35,091 inhibited arachidonic acid (800 μM) and U-46,619 (10 μM) induced aggregation with I50 values of 3 and 12 nM, respectively. In contrast, no inhibition of ADP (20 μM) induced aggregation was observed at >1000 μM. Receptor binding studies with [3H]-SQ 29,548 showed SQ 35,091 was a competitive antagonist with a K(d) value of 1.0 ± 0.1 nM in human platelet membranes. In vivo SQ 35,091 (0.2 mg/kg po) showed extended protection (T50 = 16 h) from U-46,619 (2 mg/kg iv) induced death in mice. These compounds have for the first time demonstrated that a metabolically stable interphenylene α-sidechain can be introduced into a prostanoid-like series of TxA2 antagonists with the maintenance of potent antagonistic activity.